264 related articles for article (PubMed ID: 16914240)
1. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
[TBL] [Abstract][Full Text] [Related]
2. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.
Pratt-Riccio LR; Lima-Junior JC; Carvalho LJ; Theisen M; Espíndola-Mendes EC; Santos F; Oliveira-Ferreira J; Goldberg AC; Daniel-Ribeiro CT; Banic DM
Am J Trop Med Hyg; 2005 Dec; 73(6):1096-103. PubMed ID: 16354819
[TBL] [Abstract][Full Text] [Related]
3. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria.
Dodoo D; Theisen M; Kurtzhals JA; Akanmori BD; Koram KA; Jepsen S; Nkrumah FK; Theander TG; Hviid L
J Infect Dis; 2000 Mar; 181(3):1202-5. PubMed ID: 10720556
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
5. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission.
Lusingu JP; Vestergaard LS; Alifrangis M; Mmbando BP; Theisen M; Kitua AY; Lemnge MM; Theander TG
Malar J; 2005 Sep; 4():48. PubMed ID: 16194274
[TBL] [Abstract][Full Text] [Related]
6. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
Carvalho LJ; Oliveira SG; Theisen M; Alves FA; Andrade MC; Zanini GM; Brígido MC; Oeuvray C; Póvoa MM; Muniz JA; Druilhe P; Daniel-Ribeiro CT
Scand J Immunol; 2004 Apr; 59(4):363-72. PubMed ID: 15049780
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
8. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT
Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
10. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
Theisen M; Soe S; Brunstedt K; Follmann F; Bredmose L; Israelsen H; Madsen SM; Druilhe P
Vaccine; 2004 Mar; 22(9-10):1188-98. PubMed ID: 15003647
[TBL] [Abstract][Full Text] [Related]
11. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
[TBL] [Abstract][Full Text] [Related]
14. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
[TBL] [Abstract][Full Text] [Related]
15. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
[TBL] [Abstract][Full Text] [Related]
16. Distribution of IgG subclass antibodies specific for Plasmodium falciparum glutamate-rich-protein molecule in sickle cell trait children with asymptomatic infections.
Matondo Maya DW; Mavoungou E; Deloron P; Theisen M; Ntoumi F
Exp Parasitol; 2006 Feb; 112(2):92-8. PubMed ID: 16356497
[TBL] [Abstract][Full Text] [Related]
17. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
Genton B; D'Acremont V; Lurati-Ruiz F; Verhage D; Audran R; Hermsen C; Wolters L; Reymond C; Spertini F; Sauerwein R
Vaccine; 2010 Sep; 28(40):6573-80. PubMed ID: 20691266
[TBL] [Abstract][Full Text] [Related]
19. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
[TBL] [Abstract][Full Text] [Related]
20. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro.
Theisen M; Soe S; Oeuvray C; Thomas AW; Vuust J; Danielsen S; Jepsen S; Druilhe P
Infect Immun; 1998 Jan; 66(1):11-7. PubMed ID: 9423833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
